Glaukos Corporation (GKOS) Sets New 1-Year Low at $27.10

Glaukos Corporation (NYSE:GKOS)’s share price reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $27.10 and last traded at $28.65, with a volume of 696200 shares. The stock had previously closed at $30.00.

A number of equities analysts have issued reports on the company. BMO Capital Markets decreased their price objective on Glaukos Corporation from $40.00 to $38.00 and set an “outperform” rating for the company in a report on Thursday. Zacks Investment Research upgraded Glaukos Corporation from a “sell” rating to a “hold” rating in a report on Monday. Stephens reiterated an “overweight” rating and issued a $40.00 price objective (down previously from $47.00) on shares of Glaukos Corporation in a report on Monday. Cantor Fitzgerald reiterated a “buy” rating and issued a $60.00 price objective on shares of Glaukos Corporation in a report on Tuesday, November 7th. Finally, BidaskClub downgraded Glaukos Corporation from a “buy” rating to a “hold” rating in a report on Monday, September 18th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Glaukos Corporation presently has an average rating of “Buy” and a consensus price target of $46.57.

The company has a market capitalization of $946.74, a P/E ratio of 228.25 and a beta of 1.25.

Glaukos Corporation (NYSE:GKOS) last released its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.06. Glaukos Corporation had a positive return on equity of 3.50% and a negative net margin of 0.64%. The firm had revenue of $40.41 million for the quarter, compared to analysts’ expectations of $38.69 million. During the same period in the prior year, the firm posted $0.03 earnings per share. The company’s quarterly revenue was up 36.6% on a year-over-year basis. sell-side analysts predict that Glaukos Corporation will post -0.03 earnings per share for the current fiscal year.

In related news, Director Orbimed Advisors Llc sold 580,200 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $38.73, for a total transaction of $22,471,146.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Thomas William Burns sold 73,788 shares of the stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $41.36, for a total value of $3,051,871.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 655,200 shares of company stock worth $25,573,013. Insiders own 16.40% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC boosted its position in shares of Glaukos Corporation by 7.2% during the third quarter. Janus Henderson Group PLC now owns 3,344,361 shares of the medical instruments supplier’s stock valued at $110,364,000 after buying an additional 225,105 shares during the last quarter. Capital World Investors boosted its position in shares of Glaukos Corporation by 17.1% during the second quarter. Capital World Investors now owns 2,740,000 shares of the medical instruments supplier’s stock valued at $113,628,000 after buying an additional 400,000 shares during the last quarter. Bamco Inc. NY boosted its position in shares of Glaukos Corporation by 104.6% during the third quarter. Bamco Inc. NY now owns 2,194,059 shares of the medical instruments supplier’s stock valued at $72,404,000 after buying an additional 1,121,813 shares during the last quarter. William Blair Investment Management LLC boosted its position in shares of Glaukos Corporation by 4.9% during the second quarter. William Blair Investment Management LLC now owns 2,164,764 shares of the medical instruments supplier’s stock valued at $89,773,000 after buying an additional 100,320 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Glaukos Corporation by 3.4% during the second quarter. Vanguard Group Inc. now owns 1,668,345 shares of the medical instruments supplier’s stock valued at $69,187,000 after buying an additional 55,507 shares during the last quarter.

TRADEMARK VIOLATION WARNING: “Glaukos Corporation (GKOS) Sets New 1-Year Low at $27.10” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.com-unik.info/2017/11/17/glaukos-corporation-gkos-sets-new-1-year-low-at-27-10.html.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

What are top analysts saying about Glaukos Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Glaukos Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit